|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Acusphere Inc., of Watertown, Mass., began enrollment in the first Phase I trial of its dry powder, sustained-release, microparticle formulation of an inhaled asthma drug. The product is the first candidate to enter trials under a joint venture with Elan Corp. plc, of Dublin, Ireland, which was formed to develop and commercialize a portfolio of inhalation products for local and systemic lung delivery. Acusphere's formulation is designed to slowly release the asthma drug, thereby reducing multidosing to a once-daily regimen.
Anticancer Inc., of San Diego, said its histoculture drug response assay was shown to be an effective method for in vitro drug response ...